Trial reportCritical care (London, England)2023
Remimazolam besylate versus propofol for deep sedation in critically ill patients: a randomized pilot study.
Trial report in Critical care (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 38 citations in OpenAlex.
- Non-inferiority trial of remimazolam versus propofol for fast-track anesthesia in children undergoing percutaneous closure of atrial septal defect.BMC anesthesiology · 2026Trial
- Short-term light sedation with remimazolam besylate versus propofol in the ICU (SHOSREB): a multicentre, randomized, single-blind, controlled trial.Intensive care medicine · 2026Trial
- Comparing the efficacy of fospropofol with propofol and midazolam for goal-directed sedation in critically ill patients: a prospective, open-label, pilot, randomized controlled trial.BMC anesthesiology · 2026Trial
- Comparison of Remimazolam and Propofol for Anesthesia Management in Liver Cancer Patients Undergoing Percutaneous Radiofrequency Ablation: A Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- Comparison of remimazolam besylate and dexmedetomidine on stress response and immune balance in patients with acute respiratory distress syndrome.Irish journal of medical science · 2025Trial
- Fospropofol disodium versus Propofol for deep sedation in critically ill patients: a randomized pilot study.BMC anesthesiology · 2025Trial
- Comparison of hypotension incidence between remimazolam and propofol in patients with hypertension undergoing neurosurgery: prospective, randomized, single-blind trial.BMC anesthesiology · 2024Trial
- Article
- Remimazolam besylate in the intensive care unit: emerging evidence, unresolved questions, and a potential clinical niche.Intensive care medicine · 2026Article
- Efficacy and safety of remimazolam besylate in patients receiving mechanical ventilation: A randomized phase Ⅱa trial.Journal of intensive medicine · 2026Article
- Efficacy and safety of remimazolam tosylate for sedation in ICU patients: A multicenter, randomized, phase 2 study.Journal of intensive medicine · 2026Article
- Effect and hemodynamics of remimazolam besylate on sedation of mechanically ventilated patients: a propensity score-matched study.BMC anesthesiology · 2026Observational
- Sedation with remimazolam besylate versus midazolam in acute respiratory distress syndrome patients supported by venovenous extracorporeal membrane oxygenation: a study protocol for a multicenter prospective randomized trial.Journal of thoracic disease · 2026Article
- Pharmacological profiles and mechanism of action of remimazolam for ICU sedation.Journal of intensive care · 2026Review
- Safety and efficacy of remimazolam in critical illness.Journal of intensive care · 2026Review
- Discontinuation of the development of remimazolam for ICU sedation in Japan: background and rationale.Journal of intensive care · 2026Review
- Optimal Dosing Strategies for Remimazolam Across Diverse Patient Populations: A Clinical Narrative Review.Drug design, development and therapy · 2026Review
- Effect of Remimazolam on Postoperative Delirium in Surgical ICU Patients: A Single-Center Prospective Cohort Study.Critical care research and practice · 2026Article
- Comparison of the safety and efficacy of remimazolamFrontiers in pharmacology · 2026Article
- Prolonged infusion of remimazolam in surgical and medical intensive care unit patients: a pilot pharmacokinetic study.Journal of intensive care · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the efficacy and safety of remimazolam besylate and propofol for deep sedation in critically ill patients.
methodsIn this single-center, prospective, randomized, controlled pilot study, patients in the intensive care unit (ICU) requiring deep sedation were randomized to receive remimazolam besylate or propofol intravenously. Deep sedation was defined as a Richmond Agitation and Sedation Scale (RASS) score of - 4 or - 5. Sedation depth was monitored using RASS and Narcotrend Index (NI). The primary outcome was the percentage of time within the target sedation range without rescue sedation. The secondary outcomes included ventilator-free hours within 7 days, successful extubation, length of ICU stay, and 28-day mortality. Adverse events during the interventional period were also recorded.
resultsThirty patients were assigned to each group. The median (IQR) RASS score was - 5.0 (- 5.0, - 4.0), and the median (IQR) NI value was 29.0 (21.0, 37.0) during the intervention period. Target RASS was reached a median of 100% of the sedation time in the two groups. No significant differences were observed in ventilator-free hours within 7 days, successful extubation, length of ICU stay, or 28-day mortality among groups. Hypotension occurred in 16 (53.3%) patients of remimazolam group and 18 (60.0%) patients of propofol group (p > 0.05). No patient experienced bradycardia.
conclusionsRemimazolam besylate appears to be an effective and safe agent for short-term deep sedation in critically ill patients. Our findings warrant large sample-sized randomized clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.